Clinical Trial to Evaluate the Efficacy and Safety of DWKH

NCT05683951 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2023-01-13

No results posted yet for this study

Summary

Randomized, Double-blind, Parellel, Multicenter, Active-controlled

Conditions

  • Respiratory Infection

Interventions

DRUG

DWKH

Administration of DWKH three times daily

DRUG

DWKH-R

Administration of DWKH-R three times daily

DRUG

Placebo

Administration of Placebo three times daily

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-26
Primary Completion
2022-12-09
Completion
2022-12-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05683951 on ClinicalTrials.gov